other material
confidence high
sentiment positive
materiality 0.75
NewAmsterdam Pharma reports Phase 3 BROOKLYN trial: LDL-C reduced 36.3% vs placebo at day 84, Lp(a) reduced 45.9%
NewAmsterdam Pharma Co N.V.
- LDL-C mean reduction vs placebo 36.3% at day 84 (p<0.0001), sustained at 41.5% at day 365.
- Lp(a) mean reduction vs placebo 45.9% at day 84; total LDL particles reduced 52.5% at day 180.
- Safety comparable to placebo; discontinuation rate 7.6% for obicetrapib vs 14.4% for placebo.
- Trial enrolled 354 HeFH patients; mean baseline LDL-C 123 mg/dL despite high statin use (79%) and ezetimibe (54%).
- Data presented at AHA 2024; topline from TANDEM and BROADWAY studies expected Q4 2024.